2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 6, 2017

9:00AM-11:00AM: Abstract Number: 960

ADAM-17 Is Expressed on Rheumatoid Arthritis Synovial Fibroblasts and Mediates Monocyte Migration and Adhesion

Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis Poster II: Mesenchymal Cells Do React - But How?

9:00AM-11:00AM: Abstract Number: 1443

Adverse Drug Reactions Due to Disease Modifying Drugs in a Cohort of Patients with Incident Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports

9:00AM-11:00AM: Abstract Number: 1776

Adverse Events for Discontinuation of Immunosuppressants and Outcome of Their Re-Administration in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Single Center Study in Japan

Vasculitis Poster II: ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1390

Agreement between the DAS28-ESR and the DAS28-CRP and Factors Related to the Discrepancies between Disease Activity Levels According to These 2 Scores in Patients with Early Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures

9:00AM-11:00AM: Abstract Number: 1177

Airway Findings in Patients with Relapsing Polychondritis

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

9:00AM-11:00AM: Abstract Number: 1105

Allopurinol Dose Escalation to Achieve Serum Urate below 6mg/Dl: An Open Label Extension Study

Metabolic and Crystal Arthropathies Poster I

9:00AM-11:00AM: Abstract Number: 1121

Allopurinol Treatment for Gout: How Long to Reach Serum Urate Goal?

Metabolic and Crystal Arthropathies Poster I

9:00AM-11:00AM: Abstract Number: 1326

Alpha-Glucosidase Inhibitors Alter Gut Microbiota and Ameliorate Collagen-Induced Arthritis

Rheumatoid Arthritis – Animal Models Poster II

9:00AM-11:00AM: Abstract Number: 1397

American College of Rheumatology Response Rates Determined Using 28 Versus 68/66 Joint Count in Patients with Rheumatoid Arthritis Receiving Tofacitinib in Phase 3 Studies

Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures

9:00AM-11:00AM: Abstract Number: 1737

An Abundance of Butyrate-Producing Bacterium in the Intestine and Increased Foxp3 Gene Expression of T Cells in Patients with Relapsing Polychondritis

T Cell Biology and Targets in Autoimmune Disease Poster I

9:00AM-11:00AM: Abstract Number: 1681

An Evaluation of Two Novel Techniques Utilising a Smartphone Digital Camera in the Assessment of Nailfold Capillaries in Suspected Scleroderma-Spectrum Disorders: A Single-Center Cross-Sectional Study

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster II

9:00AM-11:00AM: Abstract Number: 1107

An Illness By Any Other Name: The Effect of Changing the Disease Label of Gout on the Perceptions of the Illness and Its Management

Metabolic and Crystal Arthropathies Poster I

9:00AM-11:00AM: Abstract Number: 1012

Analysis of microRNAs in Familial Mediterranean Fever

Genetics, Genomics and Proteomics Poster II

9:00AM-11:00AM: Abstract Number: 1770

ANCA-Associated Vasculitis (AAV) in Younger Vs Older Patients: Comparison of Clinical, Serologic and Outcome Differences and Their Implications for Management

Vasculitis Poster II: ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1324

Angiotensin II Type I Receptor Deficiency Exacerbates Erosive Bone Destruction of hTNF-Transgenic Arthritis Mice

Rheumatoid Arthritis – Animal Models Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].